Dr. Lin, Yi-Ling 's publons link picture

Dr. Lin, Yi-Ling

Distinguished Research Fellow
  • 02-2789-9013 (Lab) (Room No: 443)
  • 02-2652-3902
  • 02-2785-8847 (Fax)

Specialty:
  • Molecular Virology
  • Viral Pathogenesis
  • Viral Immunology

Education and Positions:
  • 1992, PhD, University of California, Los Angeles (UCLA), USA

    2020 ~ date, CEO, Emerging Infectious Disease Division (EIDD), Biomedical Translation Research Center (BioTReC), Academia Sinica

     

    Contact Information:


Our laboratory centers on three important emerging/reemerging flaviviruses, namely Japanese encephalitis virus (JEV), dengue virus (DENV) and Zika virus (ZIKV). JEV is transmitted to humans by infected mosquitoes and causes acute encephalitis with high fatality rates. DENV generally causes a mild febrile illness called dengue fever and infrequently much more severe diseases, such as dengue hemorrhagic fever and dengue shock syndrome. ZIKV infection displays nonspecific clinical features and generally causes mild symptoms in humans. However, the recent ZIKV outbreak in Brazil has created a public health emergency of international concern. Although case fatality of ZIKV is low, maternal infection during pregnancy has been linked to congenital microcephaly. The flavivirus genome is a single-stranded, positive-sense RNA, which contains a single open reading frame encoding a polyprotein. In the infected cells this polyprotein is proteolytically cleaved into at least 11 viral structural and nonstructural proteins. Research interests in this laboratory are the molecular biology, virology, and pathogenesis mechanisms of these viruses. Our overall goal is to understand the multifaceted virus-host interactions in JEV, DENV and ZIKV infection.

There have been several dengue endemics in southern Taiwan in these years. Plus the 2003 SARS and 2015-2016 ZIKV outbreaks, these living lessons have prompted us not only to focus on basic virology research, but also to think deeply about how to deal with emerging viral infections. As a lab working on viral research, we understand the threat of an emerging infectious disease and the importance of rapid response. How can we act quickly when an epidemic occurs and do something to help the control of an outbreak have become important issues in our mindset. In respond to the COVID-19 outbreak, Academia Sinica formed a task force on Jan 28, 2020 and Dr. Yi-Ling Lin has been the coordinator of the task force. Dr. Lin is in charge of the P3 facility in IBMS and also the CEO of the newly established “Emerging Infectious Disease Division (EIDD)” in Biomedical Translation Research Center (BioTReC) located in the National Biotechnology Research Park, Nangang, Taipei. Thus, besides working on flaviviruses, our lab has also being working on SARS-CoV-2 since 2020. We have established reagents and assay systems to serve the urgent needs of testing research materials developed to fight against COVID-19.

Overall, we have chances to work with researchers inside and outside Academia Sinica, as well as commercial drug/vaccine developers on this newly emerging SARS-CoV-2. Through these practices, we got familiar with this brand-new virus and gained precious experiences of working on this emerging pathogen. We would like to further study this devastating virus and to provide more needed service for our research and industrial communities in order to develop useful detection kits, antiviral drugs and vaccines to control this global pandemic.

  1. Huang YF, Hsu FC, Wu JJ, Lin YL, Liu MT, Yang CH, Kuo HS, Chen YJ, Cheng CY, Lin HH, Liao CC, Chang CS, Liang JJ, Cheng WY, Huang JC, Chen CP, Cheng SH, Lin YC, Yang SH, Chou YJ Longitudinal neutralizing antibody responses after SARS-CoV-2 infection: A convalescent cohort study in Taiwan. Journal of microbiology, immunology, and infection 56(3), 506-515 (2023-06) [JCR] [WOS]
  2. Yen LC, Chen HW, Ho CL, Lin CC, Lin YL, Yang QW, Chiu KC, Lien SP, Lin RJ, Liao CL Neutralizing antibodies targeting a novel epitope on envelope protein exhibited broad protection against flavivirus without risk of disease enhancement. Journal of biomedical science 30(1), 41 (2023-06) [JCR] [WOS]
  3. Ko HY, Li YT, Li YY, Chiang MT, Lee YL, Liu WC, Liao CC, Chang CS, Lin YL Optimization and Improvement of qPCR Detection Sensitivity of SARS-CoV-2 in Saliva. Microbiology spectrum 11(3), e0464022 (2023-05) [JCR] [WOS]
  4. Lu RM, Liang KH, Chiang HL, Hsu FF, Lin HT, Chen WY, Ke FY, Kumari M, Chou YC, Tao MH, Yi-Ling Lin, Wu HC Broadly neutralizing antibodies against Omicron variants of SARS-CoV-2 derived from mRNA-lipid nanoparticle-immunized mice. Heliyon 9(5), e15587 (2023-04) [JCR] [WOS]
  5. Huang HC, Wang SH, Fang GC, Chou WC, Liao CC, Sun CP, Jan JT, Ma HH, Ko HY, Ko YA, Chiang MT, Liang JJ, Kuo CT, Lee TA, Morales-Scheihing D, Shen CY, Chen SY, McCullough LD, Cui L, Wernig G, Tao MH, Lin YL, Chang YM, Wang SP, Lai YJ, Li CW Upregulation of PD-L1 by SARS-CoV-2 promotes immune evasion. Journal of medical virology 95(2), e28478 (2023-01) [JCR] [WOS]
  6. Wang S, Wang CY, Kuo HK, Peng WJ, Huang JH, Kuo BS, Lin F, Liu YJ, Liu Z, Wu HT, Ding S, Hou KL, Cheng J, Yang YT, Jiang MH, Wang MS, Chen T, Xia WG, Lin E, Hung CH, Chen HJ, Shih Z, Lin YL, Ryan V, Hu MM, Heppner DG, Malherbe DC, Periasamy S, Kuzmina N, Subramani C, Hellerstein M, Monath TP, Rumyantsev A, Bukreyev A, Guirakhoo F A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2. Emerging microbes & infections 11(1), 2724-2734 (2022-12) [JCR] [WOS]
  7. Lee IJ, Lan YH, Wu PY, Wu YW, Chen YH, Tseng SC, Kuo TJ, Sun CP, Jan JT, Ma HH, Liao CC, Liang JJ, Ko HY, Chang CS, Liu WC, Ko YA, Chen YH, Sie ZL, Tsung SI, Lin YL, Wang IH, Tao MH A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern. Emerging microbes & infections 12(1), 2149353 (2022-12) [JCR] [WOS]
  8. Tang WC, Liu YT, Yeh CH, Lu CH, Tu CH, Lin YL, Lin YC, Hsu TL, Gao L, Chang SW, Chen P, Chen BC Optogenetic manipulation of cell migration with high spatiotemporal resolution using lattice lightsheet microscopy. Communications biology 5(1), 879 (2022-08) [JCR] [WOS]
  9. Lee IJ, Sun CP, Wu PY, Lan YH, Wang IH, Liu WC, Yuan JP, Chang YW, Tseng SC, Tsung SI, Chou YC, Kumari M, Lin YS, Chen HF, Chen TY, Lin CC, Chiu CW, Hsieh CH, Chuang CY, Cheng CM, Lin HT, Chen WY, Hsu FF, Hong MH, Liao CC, Chang CS, Liang JJ, Ma HH, Chiang MT, Liao HN, Ko HY, Chen LY, Ko YA, Yu PY, Yang TJ, Chiang PC, Hsu ST, Lin YL, Lee CC, Wu HC, Tao MH A booster dose of Delta x Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants. Journal of biomedical science 29(1), 49 (2022-07) [JCR] [WOS]
  10. Lee YZ, Hsu HY, Yang CW, Lin YL, Chang SY, Yang RB, Liang JJ, Chao TL, Liao CC, Kao HC, Chang JY, Sytwu HK, Chen CT, Lee SJ The Synergistic Inhibition of Coronavirus Replication and Induced Cytokine Production by Ciclesonide and the Tylophorine-Based Compound Dbq33b. Pharmaceutics 14(7), 1511 (2022-07) [JCR] [WOS]

POSTDOC
Liang, Jian-Jong
Liang, Jian-Jong
Yang, Farain
Yang, Farain
Hui-Ying, Ko
Hui-Ying, Ko
Liao, Chun-Che
Liao, Chun-Che
Chang, Chih-Shin
Chang, Chih-Shin
RESEARCH ASSOCIATES
Lee, Yi-Ling
Lee, Yi-Ling
Chang, Bi-Lan
Chang, Bi-Lan
Yu, Han-Peng
Yu, Han-Peng
Chen, Si-Yu
Chen, Si-Yu
Lee, Chih-Yin
Lee, Chih-Yin
Chiang, Ming-Tsai
Chiang, Ming-Tsai
STUDENTS
Li, Ya-Yuan
Li, Ya-Yuan
Zheng, Sheng--Huai
Zheng, Sheng--Huai
Lee, Che-Yu
Lee, Che-Yu
VISITOR
Yu, Chia-Yi
Yu, Chia-Yi
Chan, Yi-Lin
Chan, Yi-Lin
ALUMNI
Simanjuntak, Yogy
Simanjuntak, Yogy
Kao, Yu-Ting
Kao, Yu-Ting
Yeh,  Wei-Hung
Yeh, Wei-Hung
Chiu, Han
Chiu, Han
Li, Jin-Kun
Li, Jin-Kun
Lin, Ren-Jye
Lin, Ren-Jye
Yeh, Hom-Ming
Yeh, Hom-Ming
Tang, Wei-Chun
Tang, Wei-Chun
Ko, Shih-Han
Ko, Shih-Han
Tu, Yu-Chun
Tu, Yu-Chun
Chou, Min-Wei
Chou, Min-Wei
Lin, Chi-Ping
Lin, Chi-Ping
Wu, Hsin-Yi
Wu, Hsin-Yi
Chiang, Ruei-Lin
Chiang, Ruei-Lin
Yang, Jiro
Yang, Jiro
Fun, Yi-Chin
Fun, Yi-Chin
Chiu, Hsin-Ping
Chiu, Hsin-Ping
Chang, Rue-Hsin
Chang, Rue-Hsin